Scopus h-index:28
- Home
- Profiles
Ashish Atreja, MD
- About Me
- Clinical Focus
- Awards
- Locations
- Publications
- Industry Relationships
About Me
Ashish Atreja, MD, MPH completed his internal medicine and gastroenterology training at the Cleveland Clinic, Cleveland, OH and joined Mount Sinai Medical Center in July 2013. He has formal training and experience in public health and informatics. Dr. Atreja's clinical interests are inflammatory bowel disease (IBD) including Crohn's disease and ulcerative colitis, recurrent clostridium difficile infection, diarrhea, upper endoscopy, colonoscopy and fecal microbiota transplantation (FMT), also referred to as stool transplant. Dr. Atreja believes in providing culturally-sensitive, patient-centered care through education, counseling and empowerment. He is currently accepting patients from New York Metropolitan area as well as out-of state referrals for second-opinion.
Language
Position
About Me
Ashish Atreja, MD, MPH completed his internal medicine and gastroenterology training at the Cleveland Clinic, Cleveland, OH and joined Mount Sinai Medical Center in July 2013. He has formal training and experience in public health and informatics. Dr. Atreja's clinical interests are inflammatory bowel disease (IBD) including Crohn's disease and ulcerative colitis, recurrent clostridium difficile infection, diarrhea, upper endoscopy, colonoscopy and fecal microbiota transplantation (FMT), also referred to as stool transplant. Dr. Atreja believes in providing culturally-sensitive, patient-centered care through education, counseling and empowerment. He is currently accepting patients from New York Metropolitan area as well as out-of state referrals for second-opinion.
Language
Position
About Me
Ashish Atreja, MD, MPH completed his internal medicine and gastroenterology training at the Cleveland Clinic, Cleveland, OH and joined Mount Sinai Medical Center in July 2013. He has formal training and experience in public health and informatics. Dr. Atreja's clinical interests are inflammatory bowel disease (IBD) including Crohn's disease and ulcerative colitis, recurrent clostridium difficile infection, diarrhea, upper endoscopy, colonoscopy and fecal microbiota transplantation (FMT), also referred to as stool transplant. Dr. Atreja believes in providing culturally-sensitive, patient-centered care through education, counseling and empowerment. He is currently accepting patients from New York Metropolitan area as well as out-of state referrals for second-opinion.
Language
Position
Clinical Focus
- Antibiotic-Associated Colitis-C Difficile
- Celiac Disease
- Colon Polypectomy
- Colon Polyps
- Colonoscopy
- Colorectal Cancer
- Constipation
- Crohn's Disease
- Diarrhea
Show More
- Antibiotic-Associated Colitis-C Difficile
- Celiac Disease
- Colon Polypectomy
- Colon Polyps
- Colonoscopy
- Colorectal Cancer
- Constipation
- Crohn's Disease
- Diarrhea
- Endoscopic Band Ligation
- Flexible Sigmoidoscopy
- Gastroenterology
- Inflammatory Bowel Disease
- Malabsorption
- Peptic Ulcer
- Short Bowel Syndrome
- Ulcerative Colitis
- Upper GI Endoscopy
Awards
2013
Performed the first fecal microbiota transplantation in Mount Sinai Medical Center
Received NIH K23 award for improving quality of life and quality of care among patients with Inflammatory Bowel Disease.
2011
Nominated as Editor for Online Education at American Gastroenterology Association (AGA)
2009
Fellow representative to American Gastroenterology Association (AGA) Editorial Board for Online Education.
2008
Invited Presentation at Society of Healthcare Epidemiology of America (SHEA) 18th Annual Scientific Meeting, Orlando, Fl.
2008
Awarded fellowship (FACP ) to American College of Physicians.
2006
Awarded Distinquished poster award at AMIA Spring Meet, Phoenix, AZ
2006
Invited Presentation at Center for Disease Control (CDC) on using electronic health records for infection control and biosurveillance, Atlanta, GA.
2005
Nominated for the top ten papers (distinguished papers) at AMIA Annual Meet, Washinton, DC.
2005
Awarded the best merit paper at ACP-OHIO Annual Meet, Cleveland, OH.
2000
Recipient of National Delta Omega Awards for excellence in Public Health, Chicago, IL.
1993
National award for standig among the top 25 students in India selected for physics Olympiad
1993
First in the State and 7th in the nation in medical entrance examination
1991
National Talent Search Scholarship, Govt. of India
Locations
Publications
Article:59
Review Article:18
Comment/Debate:5
Letter:4
Editorial:1
Chapter:1
Recent Artifacts
- Real-world impact of vaccination on coronavirus disease 2019 (COVID-19) incidence in healthcare personnel at an academic medical center
- Digital Health Technologies for Remote Monitoring and Management of Inflammatory Bowel Disease: A Systematic Review
- Biopsy and blood-based molecular biomarker of inflammation in IBD
- Predictive approaches for acute dialysis requirement and death in COVID-19
- Impact of Digital Health Monitoring in the Management of Inflammatory Bowel Disease
- Fecal Microbiota Transplantation Is Highly Effective in Real-World Practice: Initial Results From the FMT National Registry
- Real-world impact of vaccination on COVID-19 incidence in health care personnel at an academic medical center
- Telemedicine Across the Globe-Position Paper From the COVID-19 Pandemic Health System Resilience PROGRAM (REPROGRAM) International Consortium (Part 1)
- Project TOPS: Team-Based Oversight of Patient Satisfaction Through Real-Time Interdisciplinary Feedback
- Digital triage for people with multiple sclerosis in the age of COVID-19 pandemic
Industry Relationships
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Below are financial relationships with industry reported by Dr. Atreja during 2022 and/or 2023. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Company Founder:
- Responsive Health
Consulting:
- OSHI
- Carium
- Roche genentech
Equity (Stock or stock options valued at greater than 5% ownership of a publicly traded company or equity of any value in a privately held company)
- virtuous heatlh
- Responsive Health
Other activities: Examples include, but are not limited to, committee participation, data safety monitoring board (DSMB) membership
- OSHI
- Responsive Health
- Carium
- Virtuous Health
Scientific Advisory Board:
- CaseAtlas
Service on Board of Directors: Service in a fiduciary capacity, such as an officer or director, for the following companies:
- NODEHealth Foundation
- Responsive Health
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.